Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Tactics for Bolstering the Rheumatology Workforce

Mike Fillon  |  February 13, 2020

ATLANTA—The rheumatology profession faces a severe shortfall of practitioners that threatens the ability to address patients’ needs. “Even if we doubled the number of positions for fellowship training, we wouldn’t meet the increasing demand on our workforce,” said Marcy B. Bolster, MD, associate professor of medicine at Harvard Medical School, Boston, and director of the…

Filed under:Meeting ReportsPractice SupportWorkforce Tagged with:2019 ACR/ARP Annual MeetingAdvanced Practice Cliniciansnurse practitionerphysician assistanttelemedicineworkforce shortage

Community-Based Participatory Research Led to Patient Self-Help Programs

Mike Fillon  |  February 13, 2020

ATLANTA—The Hospital for Special Surgery (HSS), headquartered in New York City, uses community-based participatory research (CBPR) models to develop patient programs. One popular self-help program for arthritis patients evolved from a different initiative focused on orthopedic pain management, according to speakers in a session at the 2019 ACR/ARP Annual Meeting. According to Titilayo Ologhobo, MPH,…

Filed under:Meeting Reports Tagged with:2019 ACR/ARP Annual Meeting

Arkansas Rheumatology Association Tackles Rural Health Issues

Linda Childers  |  February 13, 2020

In Arkansas, where according to the Arthritis Foundation 672,000 people live with arthritis, it’s not unusual for patients to travel at least 100 miles to see a rheumatologist.1 Michael Saitta, MD, a rheumatologist at the Arthritis Center of the Ozarks, Fayetteville, and president of the Arkansas Rheuma­tology Association (ARA), says patient access is a huge…

Filed under:Professional Topics Tagged with:Access to careArkansas Rheumatology Association (ARA)healthcare accessState Rheum

Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?

Donald E. Thomas, MD, FACP, FACR, with Nathalie Costedoat-Chalumeau, MD, PhD, & Michelle Petri, MD, MPH, on behalf of the ARP Practice Committee  |  February 13, 2020

The Johns Hopkins Lupus Center, Baltimore, has described its experience using hydroxychloroquine (HCQ) levels.1 Forty-four percent of its patients had levels below 500 ng/mL (partial nonadherence); 13% were severely nonadherent (<200 ng/mL). They were shown their results and educated on HCQ adherence. Adherence then improved to 80%; those with lower HCQ levels had higher disease…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Hydroxychloroquine (HCQ)level testing

Range of Insurance Issues Challenge Rheumatology

Thomas R. Collins  |  February 12, 2020

ACR representatives updated members on recent insurance issues…

Filed under:Uncategorized

Remembering Etanercept & the Advent of the Biologic Era

Robert S. Katz, MD  |  February 10, 2020

As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…

Filed under:Biologics/DMARDsSpeak Out Rheum Tagged with:etanerceptSpeak Out Rheumatology

Are Your Patients at Risk? Advocacy Matters

Kimberly Retzlaff  |  February 6, 2020

When insurance company practices put patients at risk, advocacy is an important tool physicians can use to make a real difference. You can make a difference.

Filed under:InsuranceLegislation & Advocacy Tagged with:ACR Insurance Subcommittee (ISC)AdvocacyBrian LogginsChris MorrisDr. Chris PhillipsGovernment Affairs Committee (GAC)Norman B. Gaylis

According to MRI, Ultrasound Guidance Does Not Improve Treat-to-Target in RA

Reuters Staff  |  February 5, 2020

NEW YORK (Reuters Health)—Ultrasound guidance does not improve the effectiveness of treat-to-target therapy in rheumatoid arthritis (RA), new findings confirm. “Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy,” Dr. Ulf Sundin of Diakonhjemmet Hospital, Oslo, and colleagues write in Rheumatology….

Filed under:ConditionsRheumatoid Arthritis Tagged with:imagingMagnetic resonance imaging (MRI)MRIRheumatoid Arthritis (RA)Treat-to-TargetUltrasound

Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 5, 2020

In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…

Filed under:Drug Updates Tagged with:plaque psoriasisrisankizumabsecukinumab

Even with Insurance, Fewer Americans Seeing Primary Care Providers

Lisa Rapaport  |  February 4, 2020

(Reuters Health)—Almost half of U.S. adults with private health insurance are not visiting primary care providers for routine care or sick visits, a new study suggests. Between 2008 and 2016, the number of annual primary care visits for every 100 people with private health insurance declined by 22%, from 169.5 to 134.3, the study found….

Filed under:Professional Topics

  • « Previous Page
  • 1
  • …
  • 108
  • 109
  • 110
  • 111
  • 112
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences